Evidence map›Paper›PMID 28066515›Full record

ArticleCurrent therapeutic research, clinical and experimental

A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life.

Akira Mizuki, Masayuki Tatemichi, Terue Sakakibara, Yukihiko Miura, Shigeyuki Zeki, Mitsuru Ohata, Kenji Matsuo, Fumio Kawamura, Hiroshi Nagata

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current therapeutic research, clinical and experimental. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Antireflux band mucosectomy: a novel minimally invasive approach for the treatment of refractory gastroesophageal reflux disease.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2022
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Akira MizukiDepartment of Internal Medicine, Keiyu Hospital, Yokohama, Japan.
Masayuki TatemichiDepartment of Preventive Medicine, Tokai University School of Medicine, Isehara, Japan.
Terue SakakibaraSakakibara Clinic, Yokohama, Japan.
Yukihiko MiuraMinatomirai Naika Clinic, Yokohama, Japan.
Shigeyuki ZekiTokui Medical Clinic, Yokohama, Japan.
Mitsuru OhataHiranuma Clinic, Yokohama, Japan.
Kenji MatsuoMatsuo Clinic, Yokohama, Japan.
Fumio KawamuraKawamura Clinic, Yokohama, Japan.
Hiroshi NagataDepartment of Preventive Medicine, Tokai University School of Medicine, Isehara, Japan.
Tokai University · JPKawamura Hospital · JPkeiyu Hospital · JPSakakibara Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 20% to 40% of patients with gastroesophageal reflux disease (GERD) are refractory to standard-dose proton-pump inhibitor (PPI) treatment.

objectiveWe compared the efficacy and quality-of-life effects of 20 mg once daily (QD) versus 10 mg twice daily (BID) rabeprazole (RPZ) in patients with refractory GERD-related symptoms and sleep disturbances.

methodsThis multicenter, prospective, randomized, open-label study included patients in whom PPI treatment >4 weeks was ineffective. According to the Global Overall Symptom (GOS) scale, PPI-refractory GERD was defined as ≥1 category with >3 points among 10 specific upper gastrointestinal symptoms. Seventy-eight patients were randomly assigned to 20 mg QD and 10 mg BID RPZ groups for 8 weeks. Efficacy was evaluated using self-reported questionnaires, including the GOS scale and Pittsburg Sleep Quality Index (PSQI), whereas quality of life was assessed using the Short-Form 8 Health Survey (SF-8), at 4 and 8 weeks. Patients showing improvement at 8 weeks received follow-up every 4 to 8 weeks.

resultsGOS scale scores were significantly improved at 8 weeks in both groups, with no significant intergroup differences. Although SF-8 scores showed an increasing trend over 8 weeks in both groups, the physical component summaries in the 10 mg BID group significantly improved. The mental component summaries clearly improved in the 10 mg BID group. Of the 74 cases (4 missing), 51 (68.9%) had PSQI scores ≥5.5. PSQI scores remained unchanged during follow-up in both groups. The recurrence rate was not significantly different (46.1% vs 47.1% in the 20 mg QD and 10 mg BID groups, respectively) during the follow-up period at median (interquartile range) 24.0 (30.5) months.

conclusionsIn patients with refractory GERD, there was no significant difference in GOS scale score, PSQI, or recurrence rate between the groups. With regard to subscores of the SF-8, the 10 mg BID group might be potentially effective.

Indexed as

proton-pump inhibitorquality of liferefractory gastroesophageal reflux diseasesleep disturbances

Identifiers

PMID28066515
PMCPMC5200872
OpenAlexW2549182595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.